Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01298141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
August 10, 2011
Completion date
September 25, 2017
Enrollment
171 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease